The proportions of individuals carrying APOE ε4 homozygous or heterozygous genotypes alongside protective or disease-modifying variants, within the total population, total ε4/ε4 carriers, and total ε4 carriers across each ancestry, combined across all biobanks, in AD, related dementias, and controls are reported in Figure 5, Supplementary Figure 4 and Supplementary Table 12. This evidence concerns the gene APOE and Alzheimer disease.